CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
Presented by CURE®, a collection of resources that provide information and support for patients with squamous cell carcinoma and the professionals who treat them.
June 25th 2018
The FDA has accepted a supplemental biologics license application (sBLA) for the use of Keytruda (pembrolizumab) as an adjuvant treatment for patients with resected, high-risk stage 3 melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
June 22nd 2018
In melanoma, combining two immunotherapies may lower costs and improve quality of life.
June 21st 2018
Novel immunotherapies either release the immune system’s parking brake or hit its gas pedal.
June 20th 2018
Oncolytic, or engineered, viruses that infect and kill cancer cells are showing promise.
June 19th 2018
Checkpoint inhibitors can be extremely effective for the right patients, but identifying who will benefit remains an imprecise science.
A new expert guideline for managing immunotherapy’s side effects has been released.
June 15th 2018
Study findings published in the Journal of the American Academy of Dermatology showed that once-daily aspirin use can increase the risk of melanoma in men — nearly double that of men who do not use aspirin each day.
June 14th 2018
Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Age shouldn't be a determining factor in giving a patient with melanoma immunotherapy. In fact, one study found that older patients actually do better on checkpoint blockades.
June 11th 2018
Recognize birthdays, but most importantly, keep hope, says a breast cancer and melanoma survivor.
May 29th 2018
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.
May 22nd 2018
Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.
One melanoma survivor offers advice for Skin Cancer Awareness Month.
May 4th 2018
I think being an athlete is what saved my life.
If I ever got sick or injured I would go to the children’s hospital, but that was nothing like a real hospital where people are fighting for their life day-in and day-out. I absolutely hated it, and still do. I was in Emory Hospital visiting my dad two to three times a week for about six months, and every time I walked in that place, it just gave me the heebie-jeebies.
May 3rd 2018
Mike Schmidt developed stage 3 melanoma after years of playing professional baseball for the Philadelphia Phillies.
May 2nd 2018
After radiation, as the skin heals, a compassionate dermatologist can help us to monitor any lingering side-effects.
May 1st 2018
The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.
April 30th 2018
May is skin cancer awareness month, and a good reminder to schedule an appointment with your dermatologist.
April 25th 2018
Age should not limit which patients with metastatic melanoma receive immunotherapy.
April 19th 2018
For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses.
April 16th 2018
Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.
March 27th 2018
"I have grown as a person since becoming a cancer survivor," says breast cancer and melanoma survivor Barbara Tako.
March 22nd 2018
After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.
March 21st 2018
A recent study conducted at UCLA showed that nearly all patients with uveal melanoma reported having unmet psychologic and informational needs, especially in the few months following their diagnosis.
March 6th 2018
Breast cancer survivors says that even though cancer is big, scary and demanding, it never justifies bad behavior as a person.
The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.
February 17th 2018
Gratitude helps get this cancer survivor through her cancer days, fears and worries.
February 14th 2018
While obesity is a known risk factor for more than a dozen types of cancer – and poised to take over smoking as the leading preventable cause for the disease – it may actually play a beneficial role in men with metastatic melanoma, according to a recent study published in Lancet Oncology.
This breast cancer and melanoma survivor sometimes likes to pretend and ponder about what life would have been if she hadn't gotten cancer.
Trodelvy Lengthens Time to Disease Progression in Metastatic Breast Cancer
The Journey to a Healthy Lifestyle After Cancer
Getting Out of the Woods: Strategies to Cope With Fear of Cancer Recurrence
Cancer Made Me Appreciate the Small Things in Life